What drug class is ticagrelor in?
Ticagrelor is an antiplatelet medicine that blocks the P2Y12 receptor. It belongs to the chemical drug class known as a cyclopentyl-triazolo-pyrimidine (a “Cangrelor/ticlopidine-like” structural class), and clinically it is used as a P2Y12 inhibitor to reduce the risk of clot-related events such as myocardial infarction and stroke.
How does ticagrelor work compared with other antiplatelet drugs?
Ticagrelor’s key action is P2Y12 receptor inhibition on platelets, which reduces platelet activation and aggregation. This places it in the same functional category as other P2Y12 inhibitors, but with different pharmacologic properties than thienopyridines (like clopidogrel and prasugrel).
What is ticagrelor typically used for?
Ticagrelor is used in settings where doctors want stronger inhibition of platelet clot formation, including after acute coronary syndromes (ACS) and for some patients with coronary artery disease, where it is commonly combined with aspirin as part of dual antiplatelet therapy.
Is ticagrelor the same class as clopidogrel or prasugrel?
They are related at the level of therapeutic function (both are P2Y12 inhibitors), but they are not the same chemical subclass. Ticagrelor is a non-thienopyridine P2Y12 inhibitor, whereas clopidogrel and prasugrel are thienopyridines.
What side effects or risks are associated with this class?
Because ticagrelor prevents platelet aggregation, the main class-related risk is bleeding. Other adverse effects that patients ask about often include shortness of breath (dyspnea) in some cases, which is reported more commonly with ticagrelor than with some other P2Y12 inhibitors.